Topic is suspended
| Status | Suspended |
| Decision | Selected |
| Process | TA |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 March 2021 | The Topic Selection Oversight Panel concluded that as a new formulation of an already existing agent, Pertuzumab–trastuzumab with chemotherapy is not a significant licence extension to progress through to Technology Appraisal assessment. The appraisal is therefore suspended from the NICE work programme. Access to this treatment is managed through NHS England and Improvement routine commissioning. |
| 08 January 2021 | Suspended. Topic is suspended |
| 10 January 2020 | In progress. Referred October 28 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual